STX-721-101

A Study of STX-721 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR-exon-20 Insertion Mutations.

  • NKI code: M23STX
  • Company Code: STX-721-101
  • Code clinicaltrials.gov: NCT06043817

Principal investigator

Dr. G. Ruiter

Medication

STX-721 (small-molecule inhibitor targeting EGFR- and HER2-activating mutations in the kinase domain)

Summary

This study will look at how safe the drug STX-721 is and how well it works. The drug is used for the first time in humans and has been developed for patients with NSCLC with EGFR or HER2-exon-20 changes.

Read more on clinicaltrials.gov

onload